N Thatcher
Overview
Explore the profile of N Thatcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
261
Citations
3135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dingley J, Thatcher N, Williams D
Anaesthesia
. 2019 May;
74(7):868-874.
PMID: 31049934
We investigated whether low melting point phase-change waxes could be incorporated into emergency drug transport bags to attenuate the known temperature extremes their contents can be exposed to. We exposed...
2.
Bonomi P, Gandara D, Hirsch F, Kerr K, Obasaju C, Paz-Ares L, et al.
Ann Oncol
. 2018 Jun;
29(8):1701-1709.
PMID: 29905778
Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR...
3.
Lesaffre E, Edelman M, Hanna N, Park K, Thatcher N, Willemsen S, et al.
Ann Oncol
. 2017 Feb;
28(7):1419-1426.
PMID: 28184431
Background: Pre-planned futility analyses are commonly used in oncology studies. The LUME-Lung 2 study (NCT00806819; 1199.14) was stopped early based on a pre-planned, non-binding futility analysis of investigator-assessed progression-free survival...
4.
Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R, et al.
Ann Oncol
. 2016 May;
27(8):1573-9.
PMID: 27207107
Background: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. Here, we report additional outcomes for the subpopulation of patients with...
5.
Grant P, Ayuk J, Bouloux P, Cohen M, Cranston I, Murray R, et al.
Eur J Clin Invest
. 2015 Sep;
45(11):1218.
PMID: 26343423
No abstract available.
6.
Califano R, Tariq N, Compton S, Fitzgerald D, Harwood C, Lal R, et al.
Drugs
. 2015 Jul;
75(12):1335-48.
PMID: 26187773
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs...
7.
Mitchell P, Thatcher N, Socinski M, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al.
Ann Oncol
. 2015 Feb;
26(6):1134-1142.
PMID: 25722382
Background: Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit with tecemotide versus placebo in an...
8.
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard J, et al.
Ann Oncol
. 2013 Sep;
24(11):2875-80.
PMID: 24050956
Background: Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). Patients And Methods: An FORTIS-M...
9.
Ciuleanu T, Tsai C, Tsao C, Milanowski J, Amoroso D, Heo D, et al.
Lung Cancer
. 2013 Sep;
82(2):276-81.
PMID: 23992877
Background: Molecularly targeted agents for non-small cell lung cancer (NSCLC) can provide similar efficacy to chemotherapy without chemotherapy-associated toxicities. Combining two agents with different modes of action could further increase...
10.
Smit E, Socinski M, Mullaney B, Myrand S, Scagliotti G, Lorigan P, et al.
Ann Oncol
. 2011 Dec;
23(7):1723-9.
PMID: 22186609
Background: Clinical results of a randomized phase III trial comparing pemetrexed-carboplatin (PC) with etoposide-carboplatin (EC) in chemonaive patients with extensive-stage disease small-cell lung cancer (ED-SCLC) resulted in trial closure for...